Jackson added that while there might be some anxiety about side effects, the data showed no increase in AEs with depemokimab. "And when we do see side effects with biologics, it doesn't last the ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for ... who received placebo; these effects were seen early and were ...

Depemokimab is a monoclonal antibody targeting ... GSK's vaccine Arexvy must include warnings about a rare neurological side effect, Guillain-Barré syndrome. Meanwhile, the company's ...

Depemokimab’s PDUFA date is set for December 16, 2025, with FDA reviewing two indications. Phase 3 trials showed significant improvements in nasal polyp size and obstruction. Get our list of 10 ...

Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, randomized, placebo ...

GSK's phase 3 trials ANCHOR-1 and ANCHOR-2 met co-primary endpoints for treating CRSwNP with depemokimab. Adverse event rates were similar between depemokimab and placebo in the trials.

SWIFT-1 and -2 trials showed depemokimab reduced exacerbation and hospitalization rates as an add-on therapy for patients with asthma with type 2 inflammation versus placebo ANCHOR-1 and -2 trials ...

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...

Depemokimab is an ultra-long-acting biologic administered once every six months. Price Action: GSK stock is up 0.80% at $39.14 during the premarket session at last check Monday. Read Next: FDA ...